BUSULFEX

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

BUSULFAN

متاح من:

TZAMAL BIO-PHARMA LTD

ATC رمز:

L01AB01

الشكل الصيدلاني:

SOLUTION FOR INJECTION

تركيب:

BUSULFAN 60 MG / 10 ML

طريقة التعاطي:

I.V

نوع الوصفة الطبية :

Required

المصنعة من قبل:

OTSUKA PHARMACEUT. DEV.& COMER.INC.,USA

المجال العلاجي:

BUSULFAN

الخصائص العلاجية:

For use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.

تاريخ الترخيص:

2015-01-31

خصائص المنتج

BUSULFEX
1
PRODUCT INFORMATION
BUSULFEX (BUSULFAN) INJECTION
1
NAME OF THE MEDICINE
BUSULFEX
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 10 mL vial of Busulfex contains 60 mg (6 mg/mL) of busulfan.
Busulfan, the active ingredient of Busulfex, is a white crystalline
solid that is only very slightly
soluble in water, sparingly soluble in acetone and slightly soluble in
ethanol.
For the full list of excipients, see Section 6.1 List of excipients.
3
PHARMACEUTICAL FORM
Solution for injection.
Busulfex is supplied as a sterile solution in 10 mL single-use clear
glass vials each containing 60
mg of busulfan at a concentration of 6 mg/mL for intravenous use.
Busulfex (Busulfan) injection is a potent cytotoxic drug that results
in profound myelosuppression at
the recommended dosage. It should be administered under the
supervision of a qualified physician who
is experienced in the use of cancer chemotherapeutic agents and in the
management of patients with
severe pancytopenia. Appropriate management of therapy and
complications is only possible when
adequate diagnostic and treatment facilities are readily available.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Busulfex (busulfan) Injection is indicated for use in combination with
other chemotherapeutic agents
and/or radiotherapy as a conditioning regimen prior to hematopoietic
progenitor cell transplantation
.
4.2
DOSE AND METHOD OF ADMINISTRATION
Busulfex should be administered intravenously via a central venous
catheter as a two-hour infusion
every 6 hours x 4 consecutive days for a total of 16 doses. All
patients should be premedicated with
appropriate anti-convulsant therapy (e.g. phenytoin, benzodiazepines)
to prevent seizures, as busulfan is
known to cross the blood brain barrier. Antiemetics of the 5-HT3 class
should be administered prior to
the first dose of Busulfex and continued on a fixed schedule through
administration of Busulfex or
considered through completion of the preparative regimen.
The usual adult dose of Busulfex in combination with cycloph